

# The prevalence and incidence of chronic wounds: a literature review

Nicholas Graves & Henry Zheng

## ABSTRACT

The epidemiological profile of chronic wounds is not well known, which prevents making good estimates of the costs that arise. This study is a comprehensive review of published data and the available epidemiological evidence for prevalence and incidence rates of chronic wounds is included. The search process revealed 854 studies, 69 of which met the selection criteria for inclusion. Of these studies, 42 were on pressure ulcer, 20 on diabetic ulcer, 10 on venous ulcer, and 3 on artery insufficiency ulcer. There was large variability among estimates and pooling data in a meta-analysis was not feasible. The study results with respect to prevalence and incidence in comparable settings provided an important insight into the potential size and scope of the health problem.

## INTRODUCTION

Chronic wounds result in significant functional impairment, reduction in quality of life, and large financial costs for patients and the health care system. Yet the epidemiological profile of chronic wounds hasn't been well established. This precludes estimation of the disease burden and so information that could improve the allocation of scarce health care resources towards prevention and management activities is missing. Knowledge of the scale of the health problem is important for policy making to improve wound care and prevention<sup>1</sup>. The present study describes the available epidemiological evidence and summarises prevalence and incidence rates of chronic wounds.

Prevalence is a measure of the proportion of people with a chronic wound at a point in time or during a time period in a defined population. The former is known as point prevalence, the latter period prevalence. Prevalence indicates the burden of chronic wounds in a defined population. The incidence of chronic wounds is a measure of the number of people with a newly developed chronic wound over a defined time period. It is also known as cumulative

incidence. It shows a rate of development of chronic wounds in a defined population. Incidence is increasingly used as an indicator of the quality of care.

Standardised pathological definition of the conditions are important for valid estimates of the epidemiology of chronic wounds. The Wound Healing Society defines a chronic wound as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integrity or that has proceeded through the repair process without establishing a sustained anatomic and functional result<sup>2</sup>. Based on their aetiologies, the Wound Healing Society classifies chronic wounds into four categories: pressure ulcer, diabetic ulcer, venous ulcer and artery insufficiency ulcer<sup>3</sup>. The present review focused on the prevalence and incidence of the four categories of chronic wounds.

## METHOD

### Search strategy

We searched electronic databases including Medline, EMBASE, CINAHL and Cochrane Library to identify relevant studies using MeSH terms 'prevalence' and 'incidence' combined with 'pressure ulcer' or 'diabetic ulcer' or 'venous ulcer' or 'artery insufficiency ulcer'. Reference lists of retrieved articles were read to identify studies eligible for inclusion. The search was limited to studies published in English from January 1980 to June 2012. The detailed search strategies are in Appendix A.

### Inclusion and exclusion criteria

Studies were included if they estimated prevalence and incidence of chronic wounds as an outcome measure. As the present study focused on pressure ulcer, diabetic ulcer, venous ulcer and artery insufficiency ulcer, studies were excluded if they did not specifically report prevalence or incidence as an outcome measure for one of the four categories of chronic wounds. The search process is in Appendix B.

### Nicholas Graves\*

PhD Econ, Principal Research Fellow, School of Public Health and Social Work, Queensland University of Technology, QLD, Australia  
Tel 07 3138 6115  
Email n.graves@qut.edu.au

### Henry Zheng

PhD in Public Health, Research Fellow, Exercise Medicine Australia

\* Corresponding author

## RESULTS

The search strategy yielded 854 studies, 69 of which met the selection criteria for inclusion. Of the 69 included studies, 42 were on pressure ulcer, 20 on diabetic ulcer, 10 on venous ulcer, and 3 on artery insufficiency ulcer. Three studies covered more than one category of chronic wounds. Search results are in Tables 1–4.

### Prevalence of pressure ulcer

Thirty-eight studies conducted in 11 countries reported the prevalence of pressure ulcer. Estimates varied from 1.1% to 26.7% in the hospital setting<sup>4-26</sup>, 6% to 29%<sup>8,9,27-30</sup> in the community setting, 7.6% to 53.2% in the nursing home setting<sup>5,9,26,31-33</sup>, and 13.1% to 28.7% in intensive care units (ICU)<sup>22,34</sup>. In terms of study density distribution with respect to prevalence, 35% of the studies reported a prevalence between 1.1% and 9.5%<sup>4-11,34</sup>, 46% reported a prevalence between 11.1% and 18.1%<sup>5,12-21,34</sup> and 26% reported a prevalence between 22% and 28.7% in the hospital setting<sup>15,22-26</sup>. The lowest reported prevalence was between 0.31% and 0.70% estimated as annual period prevalence among the elderly patient population in the general medical practice in the United Kingdom<sup>35</sup>. The highest reported prevalence was 53.3% among residents in a long-term care facility in Canada<sup>33</sup>. Estimates of the prevalence of different stages of pressure ulcer also varied considerably from study to study. A Canadian study<sup>36</sup> conducted in ICU reported a prevalence of 62% for stage I, 29% for stage II and

4% for stage III and IV. A Dutch study<sup>22</sup> conducted in ICU reported a much lower prevalence of 10.5% for stage I, 11.8% stage II, 5.2% for stage III and 1.3% for stage IV.

### Incidence of pressure ulcer

Twenty-six studies reported the incidence of pressure ulcer. Estimates were in a range from 0% over a 4-month period to 29% over a 6-week period in the hospital setting<sup>4,10,12,13,16-20,24,25,37-45</sup>, 6.3% over a 52-day period to 20% over a 6-week period in the community setting<sup>27-29</sup>, and 11.6%–11.7% over a period of 41–42 days in the nursing home setting<sup>33</sup>. In terms of study density distribution, 71% of the studies reported an incidence between 0% over a 4-month period to 9% over a 5-day period<sup>4,10,12,13,16,17,19,20,25,43,45</sup>, and 23% reported an incidence between 11.2% and 17.9% over a 1-year period in the hospital setting<sup>18,24,37,41</sup>. As expected, the incidence of pressure ulcer varied considerably from stage to stage. A United States (US) study reported an incidence of 21.5% for all stages of pressure ulcer and 2% for stage II–IV over a 6-day period in the hospital setting<sup>39</sup>. An Australian study reported a much lower incidence of 6.5% for all stages of pressure ulcer, and 2% for stage II–IV over a 7-day period in the hospital setting<sup>13</sup>. In the home care setting, a US study reported an incidence of 6.3% for all stages of pressure ulcer, 3.1% for stage I, 3.2% for stage II, 0.1% for stage III and 0% for stage IV over a period of 52.5 days<sup>27</sup>.

In the battle against biofilms,  
IODOSORB<sup>◇</sup> gets the job done.




- Following debridement, biofilms can return in as little as 3 days without active intervention.<sup>1</sup>
- In a recent study, IODOSORB<sup>◇</sup> was the only topical dressing capable of completely killing biofilm bacteria.<sup>2</sup>
- The significantly improved efficacy provided by IODOSORB<sup>◇</sup> may be attributed to the CADEXOMER iodine formulation which results in a sustained release that maintains iodine availability.<sup>2</sup>

IODOSORB<sup>◇</sup> – powered by CADEXOMER.

Indicated for the treatment and healing of chronic ulcers.

Australia: T 13 13 60 [www.smith-nephew.com.au/healthcare](http://www.smith-nephew.com.au/healthcare)  
New Zealand: T 0800 807 663 [www.smith-nephew.com/nz](http://www.smith-nephew.com/nz)

Bacterial biofilm detected after 72hrs<sup>2</sup>



(Graph adapted from ref. 2)

References 1. Wolcott RD, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. *J Wound Care* 2010; 19: 320-328.  
2. Phillips PL, et al. Antimicrobial dressing efficacy against mature *Pseudomonas aeruginosa* biofilm on porcine skin explants. *Int Wound J* 2013; doi:10.1111/ijw.12142.

© Smith & Nephew. Trademark of Smith & Nephew SNI1042 (10/13)

Table 1: Prevalence and incidence rates of pressure ulcer

Country	Author/year	Overall prevalence (I-IV)	Overall incidence rate (I-IV)	Prevalence rate by stage				Incidence rate by stage				Incidence duration (days)	Setting	
				I	II	III	IV	I	II	III	IV			
<b>Hospital</b>														
Netherlands	Bours <i>et al.</i> , 2001	28.7%		10.5%	11.8%	5.2%	1.3%							ICU
US	Allman <i>et al.</i> , 1995		12.9%										9 (median)	
US	Bujosa <i>et al.</i> , 2011	22% (in 2002) 25% (in 2008) 24% (in 2011)												
Singapore	Chan <i>et al.</i> , 2005	18.1%	8.1%										28	
Australia	Charlier <i>et al.</i> , 2001	12%	6.5%										7	
UK	Clark <i>et al.</i> , 1994	1.1%	4.03%										365	
Canada	Cole <i>et al.</i> , 2004	21.4%	17.9%										365	
Sweden	Gunningberg <i>et al.</i> , 2011 (Swedish university hospital) (Swedish general hospital) (US hospital)	17.6% 9.5% 6.5%												
Sweden	Gunningberg <i>et al.</i> , 2012	16.6%												
US	Hunter <i>et al.</i> , 1992	25%	0%										120	
Canada	Jacksich 1997	6.03%												
UK	James <i>et al.</i> , 2010	13.9% 26.7%												
US	Jenkins <i>et al.</i> , 2010	15.8%	2.8%	36%	34%	11%	5%						90	
Germany	Kottner <i>et al.</i> , 2009	9.2% 5% (II-IV)												
Germany	Lahmann <i>et al.</i> , 2006	24.6%												
US	Langemo 2003	13.1 %												ICU
Australia	Li <i>et al.</i> , 2011	8.9% (in 2009) 6.1% (in 2010)												
Netherlands	Schoonhoven <i>et al.</i> , 2007	6% (II-IV)	11% (II-IV) 0.06 (II-IV)										84 7	
US	Schue <i>et al.</i> , 1999	12%	6%										1 year	Rehab unit

Table 1 (continued). Prevalence and incidence rates of pressure ulcer

Country	Author/year	Overall prevalence (I-IV)	Overall incidence rate (I-IV)	Prevalence rate by stage				Incidence rate by stage				Incidence duration (days)	Setting
				I	II	III	IV	I	II	III	IV		
US	Schultz <i>et al.</i> , 1999		21.5% 2% (II-IV)									6 6	
US	Scott <i>et al.</i> , 2006		7.0-8.3*									1 year	
Spain	Soldevilla <i>et al.</i> , 2006	8.81%											
Germany	Stausberg <i>et al.</i> , 2005	5.3%	0.6%									180	Clinic
Canada	Van DenKerkhof, 2011											365	
	(in 2007)	17% (in 1998)	11.2%										
	(in 1998)	12.8%											
	(in 2006)	13.1% (II-IV)	6.8%									1 years	
US	Whittington <i>et al.</i> , 2000	15%	7%									5	Acute care
US	Whittington <i>et al.</i> , 2004	16% (in 2004)	7%									5	Acute care
		15% (in 2003)	7%									5	
		14% (in 2002)	8%									5	
		14% (in 2001)	7%									5	
		16% (in 2000)	9%									5	
		17% (in 1999)	8%									5	
Canada	Pokorny <i>et al.</i> , 2003			62%	29%	4%	4%						ICU
US	Fife <i>et al.</i> , 2001		12.4%									6.4	ICU
US	Eachempati <i>et al.</i> , 2001												ICU
	(Phase 1)		3.8% (≥II)									>7	
	(Phase 2)		8.0% (≥II)									>7	
US	Gosnell <i>et al.</i> , 1992		8.4%									3 months	
US	Meehan <i>et al.</i> , 1994	11.1% (overall)											
US	Meehan <i>et al.</i> , 1990	9.2% (overall)											
UK	Bridel <i>et al.</i> , 1996		2.2%									1 year	
UK	Clarke <i>et al.</i> , 1988		29%									≤42	

\*100,000 person-year (with pressure ulcer as primary diagnosis)

Table 1 (continued). Prevalence and incidence rates of pressure ulcer

Country	Author/year	Overall prevalence (I-IV)	Overall incidence rate (I-IV)	Prevalence rate by stage				Incidence rate by stage				Incidence duration (days)	Setting	
				I	II	III	IV	I	II	III	IV			
<b>Community</b>														
US	Bergquist <i>et al.</i> , 1999	6%	6.3%			3.1%		3.2%		0.1%		0%	52.5	Home care
US	Hanson <i>et al.</i> , 1991	13%	13%										270	Hospice
Italy	Landi <i>et al.</i> , 2007	18%												Home care
Australia	Li <i>et al.</i> , 2011	8.9% (in 2009) 6.1% (in 2010)												Community care
UK	Margolis <i>et al.</i> , 2002	0.31-0.70% (annual prev.)	0.60* 0.58* 0.57*										90 180 270	GP record
UK	Clarke <i>et al.</i> , 1988		20%										≤42	
US	Oot-Giromini <i>et al.</i> , 1993	29%	16.5%										1 year	
Spain	Soldevilla <i>et al.</i> , 2006	8.34%												
*100 person-years														
<b>Nursing home</b>														
US	Brandeis <i>et al.</i> , 1990 (Admission group) (Resident group)	17.4% 8.9%	13.2%(II-IV) 9.5% (II-IV)	6.1% 2.1%	6.3% 3.7%	2.6% 2%	2.4% 1.1%						1 year 1 year	
Spain	Casimiro <i>et al.</i> , 2002	35.7%												
Canada	Davis <i>et al.</i> , 2001 (Facility 1) (Facility 2)	36.8% 53.2%	11.7% 11.6%										41 42	
Sweden	Gunningberg <i>et al.</i> , 2012	14.5%												
Germany	Lahmann <i>et al.</i> , 2006	13.9%												
Spain	Soldevilla <i>et al.</i> , 2006	7.6%												Residential

### Prevalence of diabetic ulcer

Twelve studies conducted in eight countries reported prevalence of diabetic ulcer. Estimates varied from 1.2% to 20.4% in the hospital setting<sup>46,47</sup>, and from 0.02%–10% in the community setting<sup>9,48–56</sup>. In terms of study density distribution, 90% of the studies reported a prevalence between 0.02% and 9% in the community setting<sup>9,48–57</sup>. The highest reported prevalence was 20.4% among hospitalised diabetic patients in the Netherlands<sup>47</sup>, and the lowest was 0.02% among patients, mainly in primary health care settings in Sweden<sup>56</sup>.

### Incidence of diabetic ulcer

Ten studies reported the incidence of diabetic ulcer. Estimates were in a range between 1.8% over a 6-month period to 41% over a 12-month period in the community setting<sup>50,55,57–62</sup>. One US study reported an incidence of 5/100 person-years in the hospital setting over a 3.38-year period<sup>63</sup> and another US study reported an incidence of 68.4/1000 person-years over a 1-year period among the diabetic patient population in the community setting<sup>64</sup>. In terms of study density distribution, 75% of the studies reported an incidence between 1.8% and 5.8% over a period from six months to 3.38 years<sup>50,55,57–59,62</sup> and about 25% of the studies reported an incidence between 31.7% and 41% over a 1-year period<sup>59,61</sup>.

### Prevalence of venous ulcer

Eight studies conducted in six countries reported the prevalence of venous ulcer. Estimates ranged from 0.05% to 1% in the community setting<sup>9,56,65–67</sup>. Two studies reported an annual period prevalence of 0.26%–1.48% (over a 10-year study period)<sup>68</sup> and 1.69% in the community setting<sup>69</sup>. The prevalence was estimated to be 2.5% in the nursing home setting<sup>70</sup> and 0.05% in the hospital setting<sup>56</sup>.

### Incidence of venous ulcer

Five studies reported the incidence of venous ulcer. Estimates were in a range from 1% over a 90-day period to 2.2% over a 1-year period among residents in the long-term care facility<sup>70</sup> and 0.02% to 0.35%

over a 1-year period in the general population<sup>67</sup>. When measured in person-years, the incidence varied from 18/100,000 person-years among the general population<sup>71</sup> to 1.2/100 person-years in the GP-based elderly patient population<sup>69</sup>. One study reported marked variations in the incidence from 0.7% when venous ulcer developed at the same time as venous stasis syndrome to 3.3% when venous ulcer developed after venous stasis syndrome over a 5-year period; and from 3.7% when venous ulcer developed at the same time as venous stasis syndrome to 7.3% when venous ulcer developed after venous stasis syndrome over a 20-year period<sup>72</sup>.

### Prevalence and incidence of artery insufficiency ulcer

Data on the prevalence and incidence of artery insufficiency ulcer was scarce. Our search strategy only generated three studies. Two studies reported an overall prevalence of 0.01% in the community and primary health care setting<sup>9,56</sup>. One was a review by an international task force, which reported an incidence of 0.02%–0.35% over a 1-year period in the general population.

## DISCUSSION

This study revealed a wide variation in the estimates of the prevalence and incidence of chronic wounds among current epidemiological studies. Although a direct comparison of the wide range of the estimates was impossible, the study density distributions with respect to prevalence and incidence in comparable settings provided an important insight into the potential size and scope of the health problem.

While the study population, stage of the condition, care setting, wound risk management and care quality are expected to influence the prevalence and incidence of chronic wounds, the range of the reported variations in some estimates is difficult to interpret. For instance, a Canadian study reported a pressure ulcer prevalence of 53.2% among the residents in a long-term care facility<sup>33</sup> while a Spanish study estimated a prevalence of 7.6% among the residents in similar care settings<sup>9</sup>. The wide disparity of the epidemiological

## Jackson-Pratt® Hemaduct™ Wound Drains

Where Design and Performance Converge



## Hemaduct™ Wound Drains

A Technological Breakthrough in Design and Performance

Jackson-Pratt®, the leading name in wound drainage products, introduces **Hemaduct™** wound drains, the next generation in design and performance.

The advanced design of the Hemaduct wound drain features

- a system of multiple ducts and lumens which are interconnected through a series of **internal portals**

Portals provide

- effective distribution of suction and fluid flow throughout the entire implanted segment of the drain.
- alternate pathways for suction and fluid flow around clots and other obstructions.

**Hemaduct™** wound drains minimise tissue ingrowth and patient discomfort during wound healing and drain removal.

For further information, please contact  
Customer Service 1800 110 511



©2012 Medline Industries, Inc. Medline is a registered trademark of Medline Industries, Inc. One Medline Place, Mundelein, IL 60060. Hemaduct and Jackson-Pratt are registered trademarks of Cardinal Health, Inc. and distributed by Medline.

Table 2: Prevalence and incidence — diabetic foot ulcer

Country	Author/year	Prevalence rate	Incidence rate	Incidence duration (days)	Note
<b>Hospital</b>					
US	Boyko <i>et al.</i> , 2006		5/100 person-years	3.38 (years)	Medical centre
Egypt	El-Nahas <i>et al.</i> , 2008	1.2%			Outpatient clinic in hospital
Netherlands	Bouter <i>et al.</i> , 1993	20.4%			Diabetic patients in hospital Diabetic patients in hospital
<b>Community</b>					
Ireland	Hurley <i>et al.</i> , 2011	3.7%			In the general practice
US	Ramsey <i>et al.</i> , 1999		5.8%	3 (years)	Health maintenance organisation
Taiwan	Tseng <i>et al.</i> , 2003	2.9%			Non-type I patients in comm.
Spain	Soldevilla <i>et al.</i> , 2006	0.53% in diabetic population 0.002% (age: 15–40) 0.016% (age: 41–64) 0.085% (age: 65–74) 0.134% (age: 75–84) 0.127% (age: ≥85)			
Sweden	Ebbeskog <i>et al.</i> , 1996 (general popu.)	0.02%			primary community setting
US	LeMaster <i>et al.</i> , 2008		4.5% (predicted) 31.7% (predicted)	1 year 1 year	With no history of diabetic ulcer With history of diabetic ulcer
Tanzania	Abbas <i>et al.</i> , 2007		11% 14%	1 year 1 year	Incidence for 2005 Incidence for 2006
UK	Lincoln <i>et al.</i> , 2008		30% (intervention group) 21% (control group) 41% (intervention group) 41% (control group)	6 months 6 months 1 year 1 year	With diabetic foot history With diabetic foot history With diabetic foot history With diabetic foot history
US	Lavery <i>et al.</i> , 2003		68.4/1000 person-years 71.2/1000 person-years 63.7/1000 person-year 83.1/1000 person-year	1 year 1 year 1 year 1 year	For overall diabetic patients Non-Hispanic white Mexican Americans Other ethnic background
US	Moss <i>et al.</i> , 1992	2.4% 2.6%		1 year 1 year	Diabetic population (age<30) Diabetic population (age≥30)

Table 2 (continued). Prevalence and incidence — diabetic foot ulcer

Country	Author/year	Prevalence rate	Incidence rate	Incidence duration (days)	Note
Sweden	Borssen <i>et al.</i> , 1990	10% (patients with IDDM) 9% (patients with NIDDM)	3% (patients with IDDM) 9% (patients with NIDDM)	1 year	
US	Margolis <i>et al.</i> , 2011	8.1% /year (in 2006)			
Sweden	Rosenqvist, 1984 (annual prevalence rate in diab population)	4.4% 8.1% /year (in 2007) 8% /year (2008)			
UK	Walters <i>et al.</i> , 1992	7.4% (current and past ulcer) 2.5% (in non-diabetic group)			Home or hospital
UK	Kumar <i>et al.</i> , 1994	5.3% (in current & past ulcers)			Type 2 patients in community
Sweden	Henriksson <i>et al.</i> , 2000	5.4%	1.8%	6 months	Type 2 diabetic population
UK	Abbott <i>et al.</i> , 2002		2.2%	Annual	Community-based diabetic patients

estimates of the included studies warrants examination of potential method bias.

There was significant heterogeneity in terms of study design and data collection method among the included studies. It varied from cross-sectional study, retrospective cohort study, prospective cohort study to randomised control study. Retrospective studies had to rely on past medical records for data collection. It was impossible to ensure consistency and accuracy in assessing and recording chronic wounds. In fact, there was evidence to suggest that a high proportion of chronic wounds failed to be documented<sup>20</sup>. This could lead to under-reporting of the prevalence and incidence of chronic wounds. For cross-sectional and prospective cohort studies, some relied on direct skin examination; others used ward survey, postal survey or medical record to determine the presence or development of chronic wounds. No studies reported inter-rater reliability (IRR) testing. While most studies reported point prevalence, some reported period prevalence<sup>51,68,69</sup>. For incidence, most studies estimated cumulative incidence in percentage ratio, while others estimated incidence density rate in person-years<sup>35,40,69,71</sup>. The reported time interval of incidence varied significantly from five days to 3.38 years among the included studies. Based on the reported methodological data, it was difficult to establish comparability of chronic wound assessment and recording methods across studies. Heterogeneity in methods used in prevalence and incidence surveys has been shown to contribute to significant variations in prevalence and incidence estimates<sup>19,73,74</sup>.

The sample size and inclusion and exclusion criteria are important parameters influencing the precision of the estimates of prevalence and incidence in defined populations<sup>74-76</sup>. The sample size of the study populations in the included studies varied greatly from 30<sup>44</sup> to 40,456<sup>45</sup>. Few studies reported an a priori calculation of sample size. Most studies did not report inclusion and exclusion criteria, nor wound risk profile of the study population. Potential sample size-related bias or study population selection-related bias may have contributed to the significant variance in the prevalence and incidence estimates reported in the included studies.

Conducting a prevalence and incidence study can be time-consuming and costly. In order to produce valid, reliable and comparable epidemiological estimates to better inform clinical practice and health resource allocation for effective prevention and management of chronic wounds, it is important to ensure high methodological rigour in terms of study design, data collection, analysis and reporting. It is recommended that standardised data collection and recording protocols, including definition of study populations, specification of inclusion and exclusion criteria and study setting, identification and classification of chronic wounds, wound risk assessment, a priori calculation of sample size and IRR, be established and implemented. It is also important to ensure that surveyors or data collectors are properly trained and qualified for conducting valid data collection and recording. The recently published international guidelines on how to conduct a study on the prevalence and incidence of pressure ulcer<sup>1</sup> is essential to improving the quality and value of epidemiological studies on pressure ulcer. Similar international or national guidelines for how



Table 3: Prevalence and incidence — venous ulcer

Country	Author/year	Prevalence rate	Incidence rate	Incidence duration (days)	Note
<b>Hospital</b>					
Sweden	Ebbeskog <i>et al.</i> , 1996	0.05%			Mixed (hospital, primary, home)
<b>Community</b>					
Australia	Baker <i>et al.</i> , 1991	0.062% 0.33%			In general population In general population aged ≥60
US	Gloviczki <i>et al.</i> , 2012	0.26%/year (in 1991) 1.48%/year (in 2009/2010)			In general population
US	Heit <i>et al.</i> , 2001		18/100,000 person-years		Community population
Germany	Junger <i>et al.</i> , 2009	0.3%			Volunteers from community
UK	Margolis <i>et al.</i> , 2002	1.69%/year	1.2 /100 person-years 1.16 /100 person-years 1.13 /100 person-years	90 180 270	Elderly population GP-based
Spain	Soldevilla <i>et al.</i> , 2006	0.09% (overall) 0.001% (age:15–40) 0.05% (age:41–64) 0.24% (age:65–74) 0.44% (age:75–84) 0.75% (≥85)			Primary and residential setting
Unspecified	Clement <i>et al.</i> , 1999	0.3% (active ulcer) 1% in the adult population	0.02–0.35 %	1 year	In the general population General population assumed.
US	Mohr <i>et al.</i> , 2000		0.7%*/3.3%† 1.5%*/6.1%† 3.7%*/7.3%†	5 years 10 years 20 years	population-based
<b>Nursing home</b>					
US	Wipke-Tevis <i>et al.</i> , 2000	2.5%		90 180 270 365	Long-term care facility

\*:venous ulcer developed at the same time as venous stasis syndrome; †: venous ulcer developed after venous stasis syndrome

Table 4: Prevalence and incidence — artery insufficiency ulcer

Country	Author/year	Prevalence rate	Incidence rate	Incidence duration (days)	Note
<b>Hospital</b>					
Sweden	Ebbeskog <i>et al.</i> , 1996	0.01% (in general population)			Mixed (hospital, primary, home)
<b>Community</b>					
Spain	Soldevilla <i>et al.</i> , 2006	0.013% (overall) 0% (age:15–40) 0.006% (age:41–64) 0.039% (age:65–74) 0.057% (age:75–84) 0.127% (age:≥85)			Primary health care setting
Unspecified	Clement <i>et al.</i> , 1999 (secondary data)	0.3% (active ulcer) 1% in the adult population	0.02–0.35 %	1 year	Review by a task force General population assumed.

to conduct a study on the prevalence and incidence of other categories of chronic wounds are also needed.

This study is the first attempt to present an overview of the prevalence and incidence of pressure ulcer, diabetic ulcer, venous ulcer and artery inefficiency ulcer in one study. It has limitations. Owing to the scope of the study and insufficient data provided in the included studies, the present study did not investigate the impact casemix, wound risk profile, care quality or study setting had on the reported variations in the prevalence and incidence of chronic wounds. We mainly searched Medline, EMBASE, CINAHL and the Cochrane Library to identify relevant studies for inclusion in the present review. Therefore, it is unlikely to exhaust all the existing studies on the topic. However, we believe that the range of the epidemiological estimates identified in the present study is wide enough to provide an important indicator of the potential scale of the health problem. Although we included 'mortality' as a search term, the relevant data was scarce and we chose to only focus on the incidence and prevalence of chronic wounds in this study. Give that there was very limited epidemiological evidence available on artery insufficiency ulcer, we included secondary data from a review by an international task force<sup>67</sup>. More epidemiological study on this condition is clearly needed.

## CONCLUSION

Chronic wounds are a significant health problem confronting patients and the health care system. They require adequate health resources allocation to effectively tackle the health problem. Further epidemiological studies with high methodological rigour are needed to provide accurate estimates of the prevalence and incidence of chronic wounds, and to better inform public health decision making on effective intervention strategy for prevention and treatment of the chronic conditions.

## ACKNOWLEDGEMENT

This work has been supported by the Wound Management Innovation Cooperative Research Centre, funded by the Australian Government's Cooperative Research Centre Program.

## REFERENCES

1. International guidelines. Pressure ulcer prevention: prevalence and incidence in context. A consensus document. 2009, MEP Ltd: London.
2. Lazarus GS *et al.* Definitions and guidelines for assessment of wounds and evaluation of healing. *Arch Dermatol* 1994; 130(4):489–493.
3. The Wound Healing Society. Chronic wound care guidelines, 2006. Available from: <http://www.woundheal.org/assets/documents/final%20pocket%20guide%20treatment.pdf> (accessed 20 May 2012).
4. Clark M & Watts S. The incidence of pressure sores within a National Health Service Trust hospital during 1991. *J Adv Nurs* 1994; 20(1):33–36.
5. Gunningberg L *et al.* Exploring variation in pressure ulcer prevalence in Sweden and the USA: Benchmarking in action. *J Eval Clin Pract* 2012; 18(4):904–910.
6. Jacksich BB. Pressure ulcer prevalence and prevention of nosocomial development: one hospital's experience. *Ostomy Wound Manage* 1997; 43(3):32–40.
7. Kottner J, Tannen A & Dassen T. Hospital pressure ulcer prevalence rates and number of raters. *J Clin Nurs* 2009; 18(11):1550–1556.
8. Asimus M & Li PI. Pressure ulcers in home care settings: is it overlooked? *Wound Practice and Research* 2011; 19(2):88–97.

9. Soldevilla J *et al.* Epidemiology of chronic wounds in Spain: results of the first national studies on pressure and leg ulcer prevalence. *Wounds* 2006; 18(8):213–226.
10. Stausberg J *et al.* Pressure ulcers in secondary care: incidence, prevalence, and relevance. *Adv Skin Wound Care* 2005; 18(3):140–145.
11. Meehan M. Multisite pressure ulcer prevalence survey. *Decubitus* 1990; 3(4):14–17.
12. Chan EY *et al.* Prevalence, incidence and predictors of pressure ulcers in a tertiary hospital in Singapore. *J Wound Care* 2005; 14(8):383–4, 386–8.
13. Charlier C. Prevalence, incidence and risk: a study of pressure ulcers at a rural base hospital. *Primary Intention* 2001; 9(1): 12–13.
14. Gunningberg L *et al.* The first national pressure ulcer prevalence survey in county council and municipality settings in Sweden. *J Eval Clin Pract* 2012; 19(5):862–7.
15. James J *et al.* Pressure ulcer prevalence across Welsh orthopaedic units and community hospitals: surveys based on the European Pressure Ulcer Advisory Panel minimum data set. *Int Wound J* 2010; 7(3):147–152.
16. Jenkins ML & O'Neal E. Pressure ulcer prevalence and incidence in acute care. *Adv Skin Wound Care* 2010; 23(12):556–559.
17. Schue RM & Langemo DK. Prevalence, incidence, and prediction of pressure ulcers on a rehabilitation unit. *J Wound Ostomy Continence Nurs* 1999; 26(3):121–129.
18. VanDenKerkhof EG, Friedberg E & Harrison MB. Prevalence and Risk of pressure ulcers in acute care following implementation of Practice Guidelines: Annual Pressure Ulcer Prevalence Census 1994–2008. *Journal for Healthcare Quality: Promoting Excellence in Healthcare* 2011; 33(5):58–67.
19. Whittington KM Patrick & Roberts JL. A national study of pressure ulcer prevalence and incidence in acute care hospitals. *J Wound Ostomy Continence Nurs* 2000; 27(4):209–215.
20. Whittington KT & Briones R. National Prevalence and Incidence Study: 6-year sequential acute care data. *Adv Skin Wound Care* 2004; 17(9):490–494.
21. Meehan M. National pressure ulcer prevalence survey. *Adv Wound Care* 1994; 7(3):27–30,34,36–38.
22. Bours G *et al.* Prevalence, risk factors and prevention of pressure ulcers in Dutch intensive care units — Results of a cross-sectional survey. *Intensive Care Med* 2001; 27(10): 1599–1605.
23. Bujosa Taylor M *et al.* Prevalence of pressure ulcers in a unit of multimorbidity from 2002 to 2010. Impact of a prevention campaign. *Eur Geriatr Med* 2011; 2:S95–S96.
24. Cole L & Nesbitt C. A three-year multiphase pressure ulcer prevalence/incidence study in a regional referral hospital. *Ostomy Wound Manage* 2004; 50(11):32–40.
25. Hunter SM *et al.* Pressure ulcer prevalence and incidence in a rehabilitation hospital. *Rehabil Nurs* 1992; 17(5):239–242.
26. Lahmann NA, Halfens RJ & Dassen T. Pressure ulcers in German nursing homes and acute care hospitals: prevalence, frequency, and ulcer characteristics. *Ostomy Wound Manage* 2006; 52(2):20–33.
27. Bergquist S & Frantz R. Pressure ulcers in community-based older adults receiving home health care. *Adv Wound Care* 1999; 12(7):339–351.
28. Hanson D *et al.* The prevalence and incidence of pressure ulcers in the hospice setting: analysis of two methodologies. *Am J Hosp Palliat Care* 1991; 8(5):18–22.
29. Oot-Giromini BA. Pressure ulcer prevalence, incidence and associated risk factors in the community. *Decubitus* 1993; 6(5):24–32.
30. Landi F *et al.* Pressure ulcer and mortality in frail elderly people living in community. *Arch Gerontol Geriatr* 2007; 44(Suppl):217–223.



Applications for the Covidien 2014 Infection Control Scholarship are now open, with total funding of \$50,000 to promote excellence in Infection Control being awarded across three categories:

**For further information  
or an application form:**

Email:

[Aust.Infection.Control@Covidien.com](mailto:Aust.Infection.Control@Covidien.com)

Contact your local Covidien Product Specialist

*Applications close 1st June 2014*

COVIDIEN PTY LTD  
166 EPPING ROAD, LANE COVE NSW 2066  
AUSTRALIA 1800 252 467 (T)

## COVIDIEN 2014 Infection Control Scholarship

COVIDIEN, COVIDIEN with Logo and ™ marked brands are trademarks of Covidien AG or its affiliate. © 2014 Covidien AG or its affiliate. All rights reserved. WC 180-02-14



31. Brandeis GH *et al.* The epidemiology and natural history of pressure ulcers in elderly nursing home residents. *JAMA* 1990; 264(22):2905–2909.
32. Casimiro CA, García-de-Lorenzo A & Usán L. Prevalence of decubitus ulcer and associated risk factors in an institutionalized Spanish elderly population. *Nutrition* 2002; 18(5): 408–414.
33. Davis CM & Caseby NG. Prevalence and incidence studies of pressure ulcers in two long-term care facilities in Canada. *Ostomy Wound Manage* 2001; 47(11):28–34.
34. Langemo DK, Anderson J & Volden C. Uncovering pressure ulcer incidence. *Nurs Manage* 2003; 34(10):54–57.
35. Margolis DJ *et al.* The incidence and prevalence of pressure ulcers among elderly patients in general medical practice. *Ann Epidemiol* 2002; 12(5):321–325.
36. Pokorny ME, Koldjeski D & Swanson M. Skin care intervention for patients having cardiac surgery. *Am J Crit Care* 2003; 12(6):535–544.
37. Allman RM *et al.* Pressure ulcer risk factors among hospitalized patients with activity limitation. *JAMA* 1995; 273(11):865–870.
38. Schoonhoven L, Bousema MT & Buskens E. The prevalence and incidence of pressure ulcers in hospitalised patients in the Netherlands: a prospective inception cohort study. *Int J Nurs Stud* 2007; 44(6):927–935.
39. Schultz A *et al.* Etiology and incidence of pressure ulcers in surgical patients. *AORN J* 1999; 434,437–40,443–9.
40. Scott JR *et al.* Incidence and characteristics of hospitalized patients with pressure ulcers: State of Washington, 1987 to 2000. *Plast Reconstr Surg* 2006; 117(2):630–634.
41. Fife C *et al.* Incidence of pressure ulcers in a neurologic intensive care unit. *Crit Care Med* 2001; 29(2):283–290.
42. Eachempati SR, Hydo LJ & Barie PS. Factors influencing the development of decubitus ulcers in critically ill surgical patients. *Crit Care Med* 2001; 29(9):1678–1682.
43. Gosnell DJ, Johannsen J & Ayres M. Pressure ulcer incidence and severity in a community hospital. *Decubitus* 1992; 5(5):56–58,60,62.
44. Clarke M & Kadhom HM. The nursing prevention of pressure sores in hospital and community patients. *J Adv Nurs* 1988; 13(3):365–373.
45. Bridel J, Banks S & Mitton C. The admission prevalence and hospital-acquired incidence of pressure sores within a large teaching hospital during April 1994 to March 1995. *The fifth European Conference on Advances in Wound Management, 1996, Macmillan: London.*
46. El-Nahas MR *et al.* The prevalence of risk factors for foot ulceration in Egyptian diabetic patients. *Practical Diabetes International* 2008; 25(9):362–366.
47. Bouter KP *et al.* The diabetic foot in Dutch hospitals: epidemiological features and clinical outcome. *Eur J Med* 1993; 2(4):215–218.
48. Hurley L *et al.* The West of Ireland Diabetes Foot Study: Prevalence of risk factors for diabetic foot ulceration in Irish general practice. *Ir J Med Sci* 2011; 180:S504–S505.
49. Tseng CH. Prevalence and risk factors of diabetic foot problems in Taiwan: a cross-sectional survey of non-type 1 diabetic patients from a nationally representative sample. *Diabetes Care* 2003; 26(12):3351–3351.
50. Borssén B, Bergenheim T & Lithner F. The epidemiology of foot lesions in diabetic patients aged 15–50 years. *Diabet Med* 1990; 7(5):438–444.
51. Margolis D, Malay DS, Hoffstad OJ *et al.* Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008. *Diabetic Foot Ulcers 2011; Data Points #2.*
52. Rosenqvist U. An epidemiological survey of diabetic foot problems in the Stockholm County 1982. *Acta Med Scand Suppl* 1984; 687:55–60.
53. Walters DP *et al.* The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group. *Diabet Med* 1992; 9(4):354–358.
54. Kumar S *et al.* The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. *Diabet Med* 1994; 11(5):80–84.
55. Henriksson F *et al.* Direct medical costs for patients with type 2 diabetes in Sweden. *J Intern Med* 2000; 248(5):387–396.
56. Ebbeskog B, Lindholm C & Ohman S. Leg and foot ulcer patients. Epidemiology and nursing care in an urban population in south Stockholm, Sweden. *Scand J Prim Health Care* 1996; 14(4):238–243.
57. Abbott CA *et al.* The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. *Diabetic Med* 2002; 19(5):377–384.
58. Ramsey SD *et al.* Incidence, outcomes, and cost of foot ulcers in patients with diabetes. *Diabetes Care* 1999; 22(3):382–387.
59. Lemaster JW *et al.* Effect of weight-bearing activity on foot ulcer incidence in people with diabetic peripheral neuropathy: feet first randomized controlled trial. *Phys Ther* 2008; 88(11):1385–1398.
60. Abbas ZG & Archibald LK. Challenges for management of the diabetic foot in Africa: doing more with less. *Int Wound J* 2007; 4(4):305–313.
61. Lincoln NB *et al.* Education for secondary prevention of foot ulcers in people with diabetes: a randomised controlled trial. *Diabetologia* 2008; 51(11):1954–1961.
62. Moss SE, Klein R & Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. *Arc Intern Med* 1992; 152(3):610–616.
63. Boyko EJ *et al.* Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. *Diabetes Care* 2006; 29(6):1202–1207.
64. Lavery LA *et al.* Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. *Diabetes Care* 2003; 26(5):1435–1438.
65. Baker SR *et al.* Epidemiology of chronic venous ulcers. *Br J Surg* 1991; 78(7):864–867.
66. Junger M *et al.* Study on the epidemiology and treatment of chronic venous disease (cvi) in Pomerania, Germany. *Clin Hemorheol Microcirc* 2009; 42(3):203–204.
67. Clement DL. Venous ulcer reappraisal: insights from an international task force. *Veines International Task Force. J Vasc Res* 1999; 36(Suppl 1):42–47.
68. Głowiczki ML *et al.* Venous ulcers' prevalence study in Olmsted county — to measure the success of the venous ulcer initiative. *J Vasc Surg* 2012; 55(1):303.
69. Margolis DJ *et al.* Venous leg ulcer: incidence and prevalence in the elderly. *J Am Acad Dermatol* 2002; 46(3):381–386.
70. Wipke-Tevis DD *et al.* Prevalence, incidence, management, and predictors of venous ulcers in the long-term-care population using the MDS. *Adv Skin Wound Care* 2000; 13(5):218–224.
71. Heit JA *et al.* Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. *J Vasc Surg* 2001; 33(5):1022–1027.
72. Mohr DN *et al.* The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. *Mayo Clin Proc* 2000; 75(12):1249–1256.
73. Frantz RA. Measuring prevalence and incidence of pressure ulcers. *Adv Wound Care* 1997; 10(1):21–24.
74. Baumgarten M. Designing prevalence and incidence studies. *Adv Wound Care* 1998; 11(6):287–293.
75. Baxter H. Understanding research: 2. Ensuring reliability and validity. *J Wound Care* 2001; 10(8):329–331.
76. Prentice, JL, Stacey MC & Lewin G. An Australia model for conducting pressure ulcer prevalence surveys. *Primary Intention* 2003; 11(2):87–88,90–91,93–96,98–100,102–109.

## Appendix A: Search strategy

**Medline**

- |                                 |                                  |   |
|---------------------------------|----------------------------------|---|
| 1. MH 'Prevalence' / (159291)   | 23. MH 'Pressure Ulcer' / (8998) | 46. Stasis ulcer / (147)  |
| 2. MH 'Incidence' / (152048)    | 24. 23 AND 1 AND 2 / (145)       | 47. 46 AND 1 / (3)  |
| 3. MH 'Epidemiology' / (11189)  | 25. 23 AND 3 / (1)               | 48. 46 AND 2 / (3)  |
| 4. MH 'Mortality' / (31849)     | 26. 23 AND 4 / (15)              | 49. 46 AND 3 / (0)  |
| 5. Diabetic ulcer / (688)       | 27. OR (24–26) / (161)           | 50. 46 AND 4 / (0)  |
| 6. 5 AND 1 / (23)               | 28. Decubitus ulcer / (871)      | 51. OR (47–50) / (6)  |
| 7. 5 AND 2 / (18)               | 29. 28 AND 1 / (15)              | 52. Insufficient artery ulcer / (2244)  |
| 8. 5 AND 3 / (0)                | 30. 28 AND 2 / (21)              | 53. 52 AND 1 / (35)   |
| 9. 5 AND 4 / (0)                | 31. 28 AND 3 / (1)               | 54. 52 AND 2 / (25)   |
| 10. OR (6–9) / (40)             | 32. 28 AND 4 / (2)               | 55. 52 AND 3 / (0)  |
| 11. Diabetic foot ulcer / (495) | 33. OR (29–32) / (36)            | 56. 52 AND 4 / (0)  |
| 12. 11 AND 1 / (19)             | 34. Venous ulcer / (933)         | 57. OR (53–56) / (58)   |
| 13. 11 AND 2 / (18)             | 35. 34 AND 1 / (33)              | 58. Chronic wound / (1560)  |
| 14. 11 AND 3 / (0)              | 36. 34 AND 2 / (13)              | 59. 58 AND 1 / (21)   |
| 15. 11 AND 4 / (0)              | 37. 34 AND 3 / (0)               | 60. 58 AND 2 / (12)   |
| 16. OR (12–15) / (36)           | 38. 34 AND 4 / (0)               | 61. 58 AND 3 / (0)  |
| 17. MH 'Foot Ulcer' / (1317)    | 39. OR (35–38) / (42)            | 62. 58 AND 4 / (0)  |
| 18. 17 AND 1 / (36)             | 40. MH "Varicose Ulcer" / (3520) | 63. OR (59-62) / (31)   |
| 19. 17 AND 2 / (26)             | 41. 40 AND 1 / (48)              | 64. OR (10, 16, 22, 27, 33, 39, 45, 51, 57, 63) / (455)                                     |
| 20. 17 AND 3 / (0)              | 42. 40 AND 2 / (32)              | 65. Limiters — Date of Publication from: 19800101-20120631; English Language; Human / (391) |
| 21. 17 AND 4 / (0)              | 43. 40 AND 3 / (0)               |   |
| 22. OR (18–21) / (61)           | 44. 40 AND 4 / (0)               |   |
|                                 | 45. OR (41–44) / (74)            |   |

**EMBASE**

- |  |                                     |  |
|--|-------------------------------------|--|
| 1. 'prevalence'/exp/mj / (17490)           | 17. 'decubitus'/exp / (13216)       | 34. OR (30-33) / (80)                        |
| 2. 'incidence'/exp/mj / (9798)             | 18. 17 AND 1 / (27)                 | 35. 'artery'/exp AND 'ulcer'/exp / (2051)    |
| 3. 'epidemiology'/mj / (32785)             | 19. 17 AND 2 / (6)                  | 36. 35 AND 1 / (1)                           |
| 4. 'mortality' mj / (44489)                | 20. 17 AND 3 / (12)                 | 37. 35 AND 2 / (0)                           |
| 5. 'diabetic foot'/exp / (7394)            | 21. 17 AND 4 / (51)                 | 38. 35 AND 3 / (0)                           |
| 6. 5 AND 1 / (13)                          | 22. OR (18-21) / (89)               | 39. 35 AND 4 / (5)                           |
| 7. 5 AND 2 / (1)                           | 23. Venous and 'ulcer'/exp / (6969) | 40. OR (36-39) / (6)                         |
| 8. 5 AND 3 / (1)                           | 24. 23 AND 1 / (9)                  | 41. 'chronic' AND 'wound'/exp / (11388)      |
| 9. 5 AND 4 / (16)                          | 25. 23 AND 2 / (1)                  | 42. 41 AND 1 / (4)                           |
| 10. OR (6-9) / (31)                        | 26. 23 AND 3 / (6)                  | 43. 41 AND 2 / (0)                           |
| 11. 'diabetic'exp and 'ulcer'exp / (13582) | 27. 23 AND 4 / (12)                 | 44. 41 AND 3 / (3)                           |
| 12. 11 AND 1 / (31)                        | 28. OR (24-27) / (27)               | 45. 41 AND 4 / (11)                          |
| 13. 11 AND 2 / (4)                         | 29. 'varicosis'/exp/mj / (27710)    | 46. OR (42-45) / (18)                        |
| 14. 11 AND 3 / (10)                        | 30. 29 AND 1 / (6)                  | 47. OR (10, 16, 22, 28, 34, 40, 46) / (294 ) |
| 15. 11 AND 4 / (32)                        | 31. 29 AND 2 / (4)                  | 48. Limiters: 1980 – 2012; human / (246)     |
| 16. OR (12-15) / (98)                      | 32. 29 AND 3 / (11)                 |  |
|  | 33. 29 AND 4 / (60)                 |  |

## Appendix A (continued): Search strategy


**Cochrane Library**

- |                                   |                               |   |
|-----------------------------------|-------------------------------|---|
| 1. MH 'prevalence'/exp / (3014)   | 22. OR (18-21) / (11)         | 44. 41 AND 3 / (0)                          |
| 2. MH 'incidence'/exp / (6545)    | 23. 'pressure ulcer' / (1542) | 45. 41 AND 4 / (0)                          |
| 3. MH 'epidemiology'/exp/ (33)    | 24. 23 AND 1 / (11)           | 46. OR (42-45) / (2)                        |
| 4. MH 'mortality'/exp/ (9414)     | 25. 23 AND 2 / (49)           | 47. 'Stasis ulcer' / (116)                  |
| 5. 'diabetic ulcer' / (742)       | 26. 23 AND 3 / (0)            | 48. 47 AND 1 / (0)                          |
| 6. 5 AND 1 / (2)                  | 27. 23 AND 4 / (12)           | 49. 47 AND 2 / (0)                          |
| 7. 5 AND 2 / (5)                  | 28. OR (24-27) / (68)         | 50. 47 AND 3 / (0)                          |
| 8. 5 AND 3 / (0)                  | 29. 'Decubitus ulcer' / (172) | 51. 47 AND 4 / (0)                          |
| 9. 5 AND 4 / (7)                  | 30. 29 AND 1 / (1)            | 52. Insufficient artery ulcer / (102)       |
| 10. OR (6-9) / (14)               | 31. 29 AND 2 / (2)            | 53. 52 AND 1 / (0)                          |
| 11. 'diabetic foot ulcer' / (592) | 32. 29 AND 3 / (0)            | 54. 52 AND 2 / (0)                          |
| 12. 10 AND 1 / (2)                | 33. 30 AND 4 / (0)            | 55. 52 AND 3 / (0)                          |
| 13. 10 AND 2 / (3)                | 34. OR (30-33) / (3)          | 56. 52 AND 4 / (5)                          |
| 14. 10 AND 3 / (0)                | 35. 'venous ulcer' / (1079)   | 57. OR (53-56) / (5)                        |
| 15. 10 AND 4 / (4)                | 36. 35 AND 1 / (1)            | 58. Chronic wound / (1460)                  |
| 16. OR (12-15) / (9)              | 37. 35 AND 2 / (4)            | 59. 58 AND 1 / (3)                          |
| 17. 'foot ulcer' / (767)          | 38. 35 AND 3 / (0)            | 60. 58 AND 2 / (16)                         |
| 18. 17 AND 1 / (3)                | 39. 35 AND 4 / (7)            | 61. 58 AND 3 / (0)                          |
| 19. 17 AND 2 / (4)                | 40. OR (36-39) / (11)         | 62. 58 AND 4 / (16)                         |
| 20. 17 AND 3 / (0)                | 41. 'Varicose ulcer' / (423)  | 63. OR (59-62) / (34)                       |
| 21. 17 AND 4 / (4)                | 42. 41 AND 1 / (1)            | 64. OR (10,16,22,28,34,40,46,57,63) / (102) |
|                                   | 43. 41 AND 2 / (1)            | 65. Limiters – 1980 – 2012 (102)            |

**CINAHL**

- |                                   |                                  |  |
|-----------------------------------|----------------------------------|--|
| 1. MH 'Prevalence' / (23698)      | 22. OR (18-21) / (16)            | 44. 40 AND 4 (1)   |
| 2. MH 'Incidence' / (18341)       | 23. MH 'Pressure Ulcer' / (8998) | 45. OR (41-44) / (26)  |
| 3. MH 'Epidemiology' / (2131)     | 24. 23 AND 1 AND 2 / (78)        | 46. "Stasis ulcer" / (24)  |
| 4. MH 'Mortality' / (11538)       | 25. 23 AND 3 / (11)              | 47. 46 AND 1 / (0)   |
| 5. 'Diabetic ulcer' / (321)       | 26. 23 AND 4 / (10)              | 48. 46 AND 2 / (0)   |
| 6. 5 AND 1 / (5)                  | 27. OR (24-26) / (97)            | 49. 46 AND 3 / (0)   |
| 7. 5 AND 2 / (5)                  | 28. "Decubitus ulcer" / (108)    | 50. 46 AND 4 / (0)   |
| 8. 5 AND 3 / (0)                  | 29. 28 AND 1 / (4)               | 51. "Insufficient artery ulcer" / (182)  |
| 9. 5 AND 4 / (0)                  | 30. 28 AND 2 / (4)               | 52. 51 AND 1 / (6)   |
| 10. OR (6-9) / (10)               | 31. 28 AND 3 / (0)               | 53. 51 AND 2 / (3)   |
| 11. 'Diabetic foot ulcer' / (261) | 32. 28 AND 4 / (0)               | 54. 51 AND 3 / (0)   |
| 12. 11 AND 1 / (4)                | 33. OR (29-32) / (7)             | 55. 51 AND 4 / (1)   |
| 13. 11 AND 2 / (5)                | 34. "Venous ulcer" / (1419)      | 56. OR (52-55) / (10)  |
| 14. 11 AND 3 / (0)                | 35. 34 AND 1 / (21)              | 57. "Chronic wound" / (736)  |
| 15. 11 AND 4 / (0)                | 36. 34 AND 2 / (7)               | 58. 57 AND 1 / (5)   |
| 16. OR (12-15) / (9)              | 37. 34 AND 3 / (0)               | 59. 57 AND 2 / (4)   |
| 17. MH 'Foot Ulcer' / (688)       | 38. 34 AND 4 / (1)               | 60. 57 AND 3 / (0)   |
| 18. 17 AND 1 / (9)                | 39. OR (35-38) / (27)            | 61. 57 AND 4 / (0)   |
| 19. 17 AND 2 / (6)                | 40. MH "Varicose Ulcer" / (1313) | 62. OR (58-61) / (9)   |
| 20. 17 AND 3 / (0)                | 41. 40 AND 1 / (21)              | 63. OR (10, 16, 22, 27, 33, 39, 45, 56, 62) / (168)  |
| 21. 17 AND 4 / (1)                | 42. 40 AND 2 / (6)               | 64. Limiters: Published Date from:<br>19800101-20120631; Human; Language:<br>English / (102) |
|                                   | 43. 40 AND 3 / (0)               |  |

Appendix B: The flow chart



# Comfort Shield Incontinence Care Washcloth



- 3% dimethicone barrier seals out wetness to treat and prevent incontinence associated dermatitis
- Breathable, transparent barrier allows easy skin assessment
- All-in-one cloth saves time and maximises compliance



**Day 1:** 72-year-old patient with severely excoriated, blistered skin and extreme pain from incontinence.



**Day 4:** After 3 days using Shield® Barrier Cloths, patient's skin vastly improved; no discomfort.

Reference: Sluser S. Consistency is the key for treating severe perineal dermatitis due to incontinence. Poster presented at the Clinical Symposium on Advances in Skin and Wound care (ASWC), Las Vegas, NV 2005 Oct.



Further information:

**1300 360 226**

Mayo Healthcare Customer Service  
[www.mayohealthcare.com.au](http://www.mayohealthcare.com.au)